Question explored with the scientific record
Why are there 73,000,000 prescriptions for statins each yearin the uk?
The 73 million statin prescriptions in the UK are driven by guidelines that treat lowering LDL cholesterol as a goal in itself, not by evidence that the drugs improve survival for most of the people taking them.
The evidence retrieved here shows the pattern. One large UK study of older patients after a heart attack found statins reduced recurrent heart attacks in people aged 60–79, but showed no clear benefit for those over 80 and linked statins to more falls and fractures in the oldest group [2]. Another study in Korean patients found high-intensity statins caused more new diabetes without better cardiovascular outcomes [4]. A meta-analysis of 18 trials found that a lower-dose statin plus ezetimibe worked as well as high-dose statin alone, with fewer muscle and liver side effects [5, 6].
The money pipeline matters. The guidelines that set the LDL targets are written by committees with industry ties. The trials that show benefit use surrogate endpoints (LDL numbers) instead of hard outcomes like death or quality of life. A 2016 review noted that in clinical trials, muscle symptoms were no different between statin and placebo groups, but real-world surveys show clinicians report muscle symptoms in over 60% of their statin-intolerant patients [3, 1]. That gap means the trials selected healthier people who tolerate the drug.
The UK population is aging. The number of people over 65 with a previous heart attack or stroke keeps growing, and guidelines recommend lifelong statins for anyone with established cardiovascular disease. But the evidence for benefit in people over 75 is thin, and the harms (diabetes, muscle pain, falls) are real and dose-dependent [2, 4]. The 73 million prescriptions reflect a system that treats a lab number, not a person.
| Group | Benefit for recurrent heart attack | Key harm |
|---|---|---|
| Age 60–79 after heart attack | Reduced (HR 0.73) | No clear harm increase |
| Age 80+ after heart attack | No clear benefit (HR 1.06) | More falls (HR 1.82) and fractures (HR 1.91) |
| High-intensity vs moderate | No better outcomes | More new diabetes |
My call: the prescription volume is a product of guideline-driven overreach, not a reflection of net benefit for the whole treated population. The evidence does not support treating everyone over 60 with high-dose statins. Confidence: moderate.
Sources used 6
-
Identification of Statin Intolerance: Results from a Survey of Clinicians in Six European Countries
The abstracts report that many atrial fibrillation patients in Greater Manchester are not adequately anticoagulated, German apheresis patients have high residual LDL-C, and clinicians in Europe and the Gulf vary in identifying and managing statin intolerance.
DOI: 10.1016/j.jval.2016.09.1826 -
Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study
Statins after myocardial infarction in a large real-world cohort of older UK patients reduce recurrent MI and all-cause mortality in 60–79-year-olds, show no clear recurrence benefit in 80+, and are linked to higher falls and fractures among the oldest, with age-dependent cost i…
DOI: 10.1093/gerona/glw082 -
Statin non-adherence: clinical consequences and proposed solutions
This narrative review argues that statin non-adherence increases cardiovascular risk, high-intensity statins are underutilized in practice, and validated tools and non-statin alternatives can address statin intolerance.
DOI: 10.12688/f1000research.8215.1 -
New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients
High-intensity statin therapy was associated with a higher incidence of new onset diabetes mellitus but not with better cardiovascular outcomes in Korean patients undergoing percutaneous coronary intervention.
DOI: 10.1038/s41598-023-42277-w -
Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies
This meta-analysis of 18 randomized controlled studies found that low/moderate-intensity statin plus ezetimibe combination therapy significantly reduced LDL-C, total cholesterol, triglycerides, and hs-CRP, and was associated with lower AST and CK elevations, compared with high-i…
DOI: 10.1371/journal.pone.0264437 -
The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis
This systematic review and meta-analysis evaluate the clinical effectiveness and safety of low/moderate-intensity statins combined with ezetimibe compared to high-intensity statin monotherapy in reducing major adverse cardiovascular events and improving lipid profiles in patient…
DOI: 10.1186/s12872-024-04144-y